

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

11 Jul 2026

### Comparison effect intrauterine administration of peripheral blood lymphocyte cells on pregnancy outcome on patients with repeated implantation failure on fresh embryo transfer cycles and frozen/thawed embryo transfer cycles

#### Protocol summary

##### Study aim

The aim of this study was to determine effect of intrauterine administration of peripheral blood lymphocyte cells on pregnancy outcome on RIF's patients.

##### Design

In this clinical trial study all women who have entered in the study were divided in three groups: fresh embryo transfer, frozen/thawed embryo transfer and control group.

##### Settings and conduct

In all three groups ovulation induction was done. After oocyte retrieval, cumulus cells were removed from oocytes then sperm was injected into denuded oocytes.

##### Participants/Inclusion and exclusion criteria

This clinical trial is conducted on women who have been treated in fresh and frozen/thawed infertility treatment cycles and have a history of RIF. The criteria for entering the study include: 1. Having 3≤ failure in IVF or ICSI cycle 2. No poor ovarian reserve (FSH <15 mIU / ml) 3. No history of clinical pregnancy (primary infertility). 4. Endometrial thickness 7 < mm after ovulation induction 5. BMI <30 Exclusion criteria included: 1. History of repeated infectious diseases in the past 2. Endometriosis 3. Uterine pathologies including uterine myoma 4. Etiologies known as repeated implantation failure including chromosomal abnormalities

##### Intervention groups

1. A group of patients undergoing lymphocyte therapy in the fresh embryo transfer cycle. in these patients, 5 cc blood samples were taken in one day before day of HCG injection, and then their peripheral blood lymphocytes were isolated on the same day and 48-72hours were placed in the culture medium. On ovulation day, A single dose of 0.4 CC lymphocytes are injected into the uterus with an IUI catheter. The embryos transferred to the

uterus on the second to third day with the embryo transfer catheter. 2-Another group of patients are in the freeze embryo transfer lymphocyte therapy cycle. Five days before embryo transfer, 5 cc blood samples were taken and their peripheral blood lymphocytes were immediately isolated on the same day, and 48-72 hours were placed in the medium. Then, a single dose of 0.4 CC lymphocytes are injected into the uterus with an IUI catheter. 2-3 days after the injection of the lymphocytes, the frozen embryos are thawed and transferred to the uterus with the embryo transfer catheter. 3- control group haven't any blood sampling and lymphocyte injection into the uterus. In all three groups, support for the luteal phase is performed by administering two cyclogest vaginal suppositories for up to two weeks. The blood BHCG is measured 14 days later.

##### Main outcome variables

Finally, the outcome of pregnancy is recorded in three groups and the pregnancy rate will be compared in three groups.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20140707018381N2**

Registration date: **2017-12-03, 1396/09/12**

Registration timing: **retrospective**

Last update: **2017-12-03, 1396/09/12**

Update count: **0**

##### Registration date

2017-12-03, 1396/09/12

##### Registrant information

Name

Ahmad Hosseini

**Name of organization / entity**

Shahid Beheshti University of Medical Science

**Country**

Iran (Islamic Republic of)

**Phone**

+98 21 2235 9153

**Email address**

ahmad-hosseini@sbm.ac.ir

**Recruitment status**

**Recruitment complete**

**Funding source**

Shahid Behashti University of Medical Sciences

**Expected recruitment start date**

2016-03-19, 1394/12/29

**Expected recruitment end date**

2017-03-20, 1395/12/30

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Comparison effect intrauterine administration of peripheral blood lymphocyte cells on pregnancy outcome on patients with repeated implantation failure on fresh embryo transfer cycles and frozen/thawed embryo transfer cycles

**Public title**

Comparison effect intrauterine administration of peripheral blood lymphocyte cells on pregnancy outcome on patients with repeated implantation failur

**Purpose**

Treatment

**Inclusion/Exclusion criteria**

**Inclusion criteria:**

Inclusion criteria: at least  $\geq 3$  previous implantation failure in IVF or ICSI cycles No history of clinical pregnancy (primary infertility) No poor ovarian reserve (FSH  $< 15$  mIU/ml) Endometrial thickness  $7 <$  in ovulation induction time BMI  $< 30$

**Exclusion criteria:**

Women with history of repeated infectious diseases in the past; Endometriosis Uterine pathology such as uterine lymphomas The known etiology of recurrent implantation failure as chromosomal disorders were excluded from the study

**Age**

From **18 years** old to **50 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **160**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

By random number table couples that participated in the study divided into experiments and control groups.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description**

**Placebo**

Not used

**Assignment**

Parallel

**Other design features**

**Secondary Ids**

empty

**Ethics committees**

1

**Ethics committee**

**Name of ethics committee**

Ethics Committee of Shahid Beheshti University of Medical Sciences

**Street address**

Faculty of medicine, Arabi Ave, Daneshjo street, Velenjak, Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

1985717443

**Approval date**

2016-07-17, 1395/04/27

**Ethics committee reference number**

IR.SBMU.REC.1395.38

**Health conditions studied**

1

**Description of health condition studied**

Infertility

**ICD-10 code**

N97.9

**ICD-10 code description**

Female infertility, unspecified

**Primary outcomes**

1

**Description**

multiple pregnancy rate

**Timepoint**

14 weeks of pregnancy

**Method of measurement**

sonography

## 2

### **Description**

abortion rate

### **Timepoint**

20 weeks after pregnancy

### **Method of measurement**

sonography

## **Secondary outcomes**

## 1

### **Description**

clinical pregnancy rate

### **Timepoint**

after intervention

### **Method of measurement**

sonography

## **Intervention groups**

## 1

### **Description**

1. A group of patients undergoing lymphocyte therapy in the fresh embryo transfer cycle. In these patients, 5 cc blood samples were taken in one day before day of HCG injection, and then their peripheral blood lymphocytes were isolated on the same day and 48-72 hours were placed in the culture medium. On ovulation day, a single dose of 0.4 CC lymphocytes are injected into the uterus with an IUI catheter. The embryos transferred to the uterus on the second to third day with the embryo transfer catheter.

### **Category**

Treatment - Drugs

## 2

### **Description**

2-Another group of patients are in the frozen/thawed embryo transfer lymphocyte therapy cycle. Five days before embryo transfer, 5 cc blood samples were taken and their peripheral blood lymphocytes were immediately isolated on the same day, and 48-72 hours were placed in the medium. Then, a single dose of 0.4 CC lymphocytes are injected into the uterus with an IUI catheter. 2-3 days after the injection of the lymphocytes, the frozen embryos are thawed and transferred to the uterus with the embryo transfer catheter.

### **Category**

Treatment - Drugs

## 3

### **Description**

3. The control group haven't any blood samplings and lymphocyte injection into the uterus

### **Category**

N/A

## **Recruitment centers**

## 1

### **Recruitment center**

#### **Name of recruitment center**

Genetics & In Vitro Assisted Reproductive (GIVAR) center, Erfan hospital

#### **Full name of responsible person**

Dr. Fattaneh Farifteh

#### **Street address**

Erfan hospital, Bakhshayesh St, Sarv st., Tehran

#### **City**

Tehran

#### **Province**

Tehran

#### **Postal code**

1985717443

#### **Phone**

+98 21 2235 8435

#### **Fax**

+98 21 8867 8159

#### **Email**

f.farifteh@gmail.com

#### **Web page address**

<http://phasco.com/LabDirectory.aspx?lid=853>

## **Sponsors / Funding sources**

## 1

### **Sponsor**

#### **Name of organization / entity**

Shahid Beheshti University of Medical Sciences

#### **Full name of responsible person**

Ahmad Hosseini

#### **Street address**

Erfan hospital, Bakhshayesh St, Sarv St., Tehran

#### **City**

Tehran

#### **Province**

Tehran

#### **Postal code**

1985717443

#### **Phone**

+98 21 2235 8435

#### **Fax**

+98 21 8867 8159

#### **Email**

profhosseini@yahoo.com

#### **Web page address**

<http://phasco.com/LabDirectory.aspx?lid=853>

### **Grant name**

### **Grant code / Reference number**

### **Is the source of funding the same sponsor organization/entity?**

Yes

### **Title of funding source**

Shahid beheshti University of Medical Sciences

### **Proportion provided by this source**

100

### **Public or private sector**

Private  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Fattaneh Farifteh  
**Position**  
Academic staff  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
**Street address**  
Shahid Beheshti University of medical science, Arabi  
Ave, daneshjo st, Velenjak, Tehran  
**City**  
Tehran  
**Postal code**  
1985717443  
**Phone**  
+98 21 2243 9956  
**Fax**  
+98 21 8867 8159  
**Email**  
f.farifteh@gmail.com  
**Web page address**

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
FattanehF Farifteh  
**Position**  
Assistant Professor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Reproductive Biology  
**Street address**  
Shahid Beheshti University of medical science, Arabi  
Ave, daneshjo st, Velenjak, Tehran  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1985717443  
**Phone**  
+98 21 2235 9153  
**Fax**

+98 21 8867 8159

### Email

f.farifteh@gmail.com

### Web page address

<http://phasco.com/LabDirectory.aspx?lid=853>

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Fattaneh Farifteh  
**Position**  
Phd, Assistant Professor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Reproductive Biology  
**Street address**  
Shahid Beheshti University of medical science, Arabi  
Ave, daneshjo st, Velenjak, Tehran  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1985717443  
**Phone**  
+98 21 2235 9153  
**Fax**  
+98 21 8867 8159  
**Email**  
f.farifteh@gmail.com  
**Web page address**  
<http://phasco.com/LabDirectory.aspx?lid=853>

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Yes - There is a plan to make this available

### Statistical Analysis Plan

Yes - There is a plan to make this available

### Informed Consent Form

Yes - There is a plan to make this available

### Clinical Study Report

Yes - There is a plan to make this available

### Analytic Code

Yes - There is a plan to make this available

### Data Dictionary

Yes - There is a plan to make this available

### Title and more details about the data/document

All interventions in the patient's file will be recorded and archived in the Erfan hospital. All data obtained from this study will be released after being unidentified studies participants.

### When the data will become available and for how long

Get started 6 months after publishing study results

### To whom data/document is available

he findings of this study will be accessible to all individuals.

**Under which criteria data/document could be used**

To improve pregnancy outcomes in infertility clinics

**From where data/document is obtainable**

Dr Fattaneh Farifteh

**What processes are involved for a request to access data/document**

Receiving the author's confirmation and obtaining approval from the director of the Infertility Clinic of the Erfan Hospital

**Comments**